GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications [Yahoo! Finance]
GeoVax Labs, Inc. (GOVX)
NASDAQ:AMEX Investor Relations:
geovax.com/contact-geovax.html
Company Research
Source: Yahoo! Finance
ATLANTA, GA - September 24, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced the expansion of its oncology development strategy to include assessments of additional solid tumor targets for Gedeptin(R), its gene-directed enzyme prodrug therapy (GDEPT). Working closely with its oncology advisory team including the Winship Cancer Institute of Emory University, GeoVax is evaluating the combination of Gedeptin with immune checkpoint inhibitors in preclinical models of several solid tumor types. These models are designed to validate Gedeptin's mechanism - localized intratumoral cytotoxicity that also primes systemic immune responses - in tumor settings beyond head and neck cancer such as triple negative breast cancer and cutaneous malignancies. Phase 2 Clinical Trial GeoVax previously announced updated plans for a Phase 2 clinical trial, AdP
Show less
Read more
Impact Snapshot
Event Time:
GOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOVX alerts
High impacting GeoVax Labs, Inc. news events
Weekly update
A roundup of the hottest topics
GOVX
News
- GeoVax Labs (NASDAQ:GOVX) had its price target lowered by analysts at D. Boral Capital from $9.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- GeoVax Labs files to sell 11.9M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025 [Yahoo! Finance]Yahoo! Finance
GOVX
Earnings
- 11/13/25 - Miss
GOVX
Sec Filings
- 11/26/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- 11/7/25 - Form 424B3
- GOVX's page on the SEC website